Amalgamated Bank Sells 155 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Amalgamated Bank decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 76,006 shares of the medical equipment provider’s stock after selling 155 shares during the period. Amalgamated Bank’s holdings in Intuitive Surgical were worth $33,811,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. One Wealth Management Investment & Advisory Services LLC raised its holdings in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after acquiring an additional 23 shares in the last quarter. Indiana Trust & Investment Management CO lifted its position in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 25 shares during the last quarter. Hoxton Planning & Management LLC lifted its position in shares of Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares during the last quarter. First Affirmative Financial Network lifted its position in shares of Intuitive Surgical by 2.7% during the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after buying an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its position in shares of Intuitive Surgical by 2.3% during the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after buying an additional 26 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $483.32 on Wednesday. The stock has a market capitalization of $171.43 billion, a price-to-earnings ratio of 87.24, a PEG ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.18. The firm’s 50 day simple moving average is $465.50 and its 200-day simple moving average is $423.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the firm posted $1.18 EPS. The business’s revenue was up 14.5% on a year-over-year basis. Analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on ISRG shares. BTIG Research increased their price target on shares of Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. increased their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Barclays increased their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Citigroup upped their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Evercore ISI cut their price objective on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $446.45.

Insider Activity

In other news, EVP Robert Desantis sold 1,413 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $438.60, for a total transaction of $619,741.80. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 2,818 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the transaction, the executive vice president now owns 298 shares in the company, valued at approximately $136,522.74. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.